NEW DRUG EFFECTIVE IN REDUCING WEIGHT BY UP TO 20%

-

 

NEW DRUG EFFECTIVE IN REDUCING WEIGHT BY UP TO 20%







According to a major global study involving UCL researchers, one third (35%) of people who took a new drug for treating obesity lost more than one-fifth (greater than or equal to 20%) of their total body weight.

The findings from the large-scale international trial, published today in the New England Journal for Medicine, are being hailed as a "gamechanger" for improving the health of people with obesity and could play a major part in helping the UK to reduce the impact of diseases, such as COVID-19.

The drug, semaglutide, works by hijacking the body's appetite-regulating system in the brain leading to reduced hunger and calorie intake.

Rachel Batterham, Professor of Obesity, Diabetes, and Endocrinology, who leads the Centre for Obesity Research at UCL and the UCLH Centre for Weight Management, is one of the paper's principal authors, almost 2,000 people in 16 countries.

Professor Batterham (UCL Medicine) said: "The findings of this study represent a major breakthrough for improving the health of people with obesity. Three quarters (75%) of people who received semaglutide 2.4mg lost more than 10% of their body weight, and more than one-third lost more than 20%. No other drug has come close to producing this weight loss level -- this really is a gamechanger. For the first time, people can achieve through drugs what was only possible through weight-loss surgery."

Professor Batterham added: "The impact of obesity on health has been brought into sharp focus by COVID-19 where obesity markedly increases the risk of dying from the virus, as well as increasing the risk of many life-limiting serious diseases including heart disease, type 2 diabetes, liver disease and certain types of cancers. This drug could have major implications for UK health policy for years to come."

The average participant in the trial lost 15.3kg (nearly 3 stone); this was accompanied by reductions in risk factors for heart disease and diabetes, such as waist circumference, blood fats, blood sugar, blood pressure, and reported improvements in overall quality of life.

The trial's UK Chief Investigator, Professor John Wilding (University of Liverpool), said: "This is a significant advance in the treatment of obesity. Semaglutide is already approved and used clinically at a lower dose for the treatment of diabetes, so as doctors, we are already familiar with its use. For me, this is particularly exciting as I was involved in very early studies of GLP1 (when I worked at the Hammersmith Hospital in the 1990s, we were the first to show in laboratory studies that GLP1 affected appetite), so it is good to see this translated into an effective treatment for people with obesity."

With evidence from this trial, semaglutide has been submitted for regulatory approval as a treatment for obesity to the National Institute of Clinical Excellence (NICE), the European Medicines Agency (EMA), and the US Food and Drug Administration (FDA).

About the trial

The Phase III 'STEP'* randomized controlled trial involved 1,961 adults who were either overweight or had obesity (average weight 105kg/16.5 stone; body mass index 38kg/m2), and took place at 129 sites in 16 countries across Asia, Europe, North America, and South America.

Participants took a 2.4mg dose of semaglutide (or matching placebo) weekly via subcutaneously (under the skin) injection, similar to the way people with diabetes inject insulin. Overall, 94.3% of participants completed the 68-week study, which started in autumn 2018.

Those taking part also received individual face-to-face or phone counseling sessions from registered dietitians every four weeks to help them adhere to the reduced-calorie diet and increased physical activity, providing guidance, behavioral strategies, and motivation. Additionally, participants received incentives such as kettlebells or food scales to mark progress and milestones.

In those taking semaglutide, the average weight loss was 15.3kg (nearly three stone), with a reduction in BMI of -5.54. The placebo group observed an average weight loss of 2.6kg (0.4 stone) with a reduction in BMI of -0.92.

Those who had taken semaglutide also saw reductions in risk factors for heart disease and diabetes, such as waist circumference, blood fats, blood sugar, and blood pressure, and reported improvements in their overall quality of life.

About the drug

Semaglutide is clinically approved for patients with type 2 diabetes, though it is typically prescribed in much lower doses of 1mg.

The drug possesses a compound structurally similar to (and mimics) the human glucagon-like peptide-1 (GLP-1) hormone released into the blood from the gut after meals.

GLP-1 induces weight loss by reducing hunger, increasing feelings of fullness, and helping people eat less and reduce their calorie intake.

While the STEP study has been through Phase I and II trials, assessing the 2.4mg doses for safety, in the Phase III trial, some participants reported side effects from the drug, including mild-to-moderate nausea and diarrhea that were transient and generally resolved without permanent discontinuation from the study.

The international trial was funded by the pharmaceutical company Novo Nordisk.

* Semaglutide Treatment Effect in People with Obesity (STEP)


Comments

  1. Hans OttoMarch 12, 2021 at 7:52 AM

    I first doubted It was not true but decided to try, when I contacted this herbal physician via his e-mail, I purchased herpes herbal medicine and received it within 7 days and used it as prescribed, I tested negative within 3 weeks use, do not loose hope to contact him early If you need help, you can contact him on email dr.chalaherbalhome@gmail.com or you can visit his website on http://drchalaherbalhome.godaddysites.com or https://mywa.link/dr.chalaherbalhome am convinced he can help you too

    ReplyDelete

Post a Comment

Popular posts from this blog

PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY

-
Image
  PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY Building on prior studies with healthy-weight participants, the new research includes different body sizes.         New research indicates that weight influences how and when bodies burn energy. An Oregon Health & Science University study published in the journal  Obesity  found people who have a healthy weight use more energy during the day, when most people are active and eat, while those who are obese spend more energy during the night when most people sleep. The study also found that during the day, those with obesity have higher levels of the hormone insulin -- a sign that the body is working harder to use glucose, an energy-packed sugar. "It was surprising to learn how dramatically the timing of when our bodies burn energy differed in those with obesity," said the study's first author, Andrew McHill, Ph.D., an assistant professor at the OHSU School of Nursing and the Oregon Institute of ...
Read more

WHAT CAUSES ITCHING, AND WHAT STOPS IT?

-
Image
  WHAT CAUSES ITCHING, AND WHAT STOPS IT?         It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a severe health problem. How does the body know when to stop? Scientists at UC San Francisco are getting close to an answer. In a breakthrough that could transform how doctors treat conditions from eczema to allergies, they have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation. The findings, published on October 13th in  Science Immunology , lay the groundwork for a new generation of drugs that interact more intelligently with the body's innate self-regulating ability. Previous approaches suggested that IL-31 signals itch and promotes skin inflammation. However, the UCSF team discovered that nerve cells, or neurons, that respond to IL-31, triggering a scratch, also prevent immune cells from overreacting and causing more ...
Read more

A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY

-
Image
  A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY         In a study with 22 pairs of identical twins, Stanford Medicine researchers and their colleagues have found that a vegan diet improves cardiovascular health in as little as eight weeks. Although it's well-known that eating less meat improves cardiovascular health, diet studies often need to be enhanced by genetic differences, upbringing, and lifestyle choices. By studying identical twins, however, the researchers were able to control for genetics and limit the other factors, as the twins grew up in the same households and reported similar lifestyles. "Not only did this study provide a groundbreaking way to assert that a vegan diet is healthier than the conventional omnivore diet, but the twins were also a riot to work with," said Christopher Gardner, Ph.D., the Rehnborg Farquhar Professor and a professor of medicine. "They dressed the same, they talked the same, and they had a banter ...
Read more